Home
About
Overview
Sharing Data
ORCID
Help
History (19)
Nivolumab treatment beyond RECIST-defined progression in recurrent or metastatic squamous cell carcinoma of the head and neck in CheckMate 141: A subgroup analysis of a randomized phase 3 clinical trial.
Prediction and validation of exenatide risk marker effects on progression of renal disease: Insights from EXSCEL.
Raltegravir Potassium
Sentinel Lymph Node
Social Discrimination
See All 19 Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password